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Lynch Syndrome is the most common hereditary cause of
colorectal cancer, caused by pathogenic mutations in the
mismatch repair (MMR) genes that result in functional
defects in the DNA mismatch repair complex. Individuals
identified with a pathogenic mutation are at high-risk of
early onset colorectal and/or endometrial tumours. How-
ever, up to 50% of MMR sequence variants are reported to
be of unknown clinical significance, creating a problem for
clinicians and patients.
We are developing a multifactorial model to assess the
pathogenicity of MMR gene sequence variants of
unknown clinical significance. Currently this model uti-
lizes data on tumour microsatellite instability (MSI) and
family segregation analysis to assess the likelihood that a
variant carrier demonstrates features expected for a carrier
of a pathogenic mutation. Tumour BRAF V600E mutation
and MLH1 promoter methylation are reported to be asso-
ciated with MSI-H, sporadic colorectal cancer and may
thus provide a strong prediction that a tumour with MSI-
H status is not from a MMR gene mutation carrier.
A literature review of BRAF V600E and MLH1 promoter
methylation in colorectal cancer patients was performed.
Frequency of these tumour features in each study was
assessed, stratified by MSI status and reported/likely
MMR gene mutation status. Frequency of these character-
istics was also analysed in the Colon CFR dataset, and
used to estimate a likelihood ratio (LR) of pathogenicity
for use in multifactorial modelling.
As expected, the literature review of 4655 individuals
from 33 studies revealed a high frequency of BRAF muta-
tions in MSI-H tumours without a MMR mutation, which
increased for the subset of cases with lack of MLH1
tumour protein expression. However, BRAF V600E muta-
tion was identified in one patient with a PMS2 mutation,
challenging previous assumptions that BRAF mutation sta-
tus excludes positive MMR gene mutation status. MLH1
promoter methylation data generated using a variety of
experimental designs were available for only 2984 indivi-
duals from 40 studies, with inconsistencies in frequency
between studies. Information was reported on methylation
status of 204 known MLH1 gene mutation carriers.
Analysis of the Colon CFR dataset showed that BRAF
tumour mutation status predicted MMR gene mutation
status when combined with tumour MSI-H status. How-
ever, MSI-L and MSS with BRAF did not provide any
additional predictive power over MSI-L or MSS status
alone. The likelihood of a tumour with MSI-H and BRAF
V600E positive status to be from a non-carrier was 11.55
and 9.85 for population-based and clinic-based patients,
respectively. However, 4/98 (4.08%) of MSI-H BRAF posi-
tive tumours were from MMR mutation carriers.
In conclusion, positive BRAF tumour status is not a
conclusive test to exclude MMR gene mutation status
for patients, but BRAF-MSI tumour status is a powerful
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